Compare Abbott Laboratories (ABT) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs PAGSEG Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while PAGSEG Inc trades at $8.73 (market cap $2.49B). The key difference: Abbott Laboratories is far larger — about 67× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.69%). Which is the better fit depends on your goals.
| ABT | PAGS | |
|---|---|---|
Market Cap | $166.94B | $2.49B |
Sector | Health | Technology |
52-Week High | $136.62 | $12.00 |
52-Week Low | $82.57 | $7.75 |
Enterprise Value | $193.69B | $10.12B |
Dividend Yield | 2.63% | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PAGS trades at $8.93, down 2.08% for the day, with a bearish technical signal from moving averages. The stock shows strong value fundamentals with a P/E of 6.32 and P/B of 0.89. Recent earnings were mixed, missing in Q1 2026 but beating in Q4 2025. The company maintains solid profitability with a 10.4% net income margin and generated positive net cash flow of $930 million in 2025. A dividend of $0.26 per share is scheduled for payment on June 1, 2026.
The investment outlook is supported by deep valuation discounts and analyst optimism, with 15 buy ratings. However, near-term headwinds include flat payment volume growth and pressure from Brazilian interest rates. The primary risk remains macroeconomic sensitivity in Brazil, while the opportunity lies in potential expansion of banking and credit operations driving future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
